Skyscraper City Forum banner
1 - 20 of 113 Posts

·
Registered
Joined
·
20,958 Posts
Discussion Starter · #1 ·
India's pharmaceutical sector will touch US$ 45 billion by 2020.

https://www.ibef.org/industry/pharmaceutical-india.aspx

Indian pharmaceutical sector accounts for about 3.1 – 3.6 per cent of the global pharmaceutical industry in value terms and 10 per cent in volume terms and is expected to grow to US$ 100 billion by 2025. India contributes the second largest share of pharmaceutical and biotech workforce in the world. In February 2018, the Indian pharmaceutical market grew at 7.1 per cent.
Let's Keep track of Pharmaceutical / Medical Devices / Bio-Tech in and around Chennai

* Medipark-India’s first infrastructure 330 acres in Chengalpet
* Integrated Vaccine Complex - Chengalpattu
* Marine Biotechnology Park-Proposed over 300 acres Mahabalipuram
* TICEL Bio-tech park - II at Chennai
* TICEL Bio-tech park - III
Right now we rank 5th in india in pharma sector and the above projects will significantly improve the position within India as well as outside.

In chengalpet there is lot of construction activity going on inside site marked as medpark so we can expect it to be operation in few years

- Courtesy Natarajan
 

·
Registered
Joined
·
20,958 Posts
Discussion Starter · #2 ·
Sanmina Achieves FDA Registration at Its Facilities in Chennai, India

Becomes First Tier 1 EMS Company in India with both FDA Registration and Medical Design Registration

SAN JOSE, Calif., April 5, 2018 /PRNewswire/ -- Sanmina Corporation (Nasdaq: SANM), a leading integrated manufacturing solutions company that makes some of the world's most complex and innovative electronic, optical and mechanical products, today announced that it has received FDA registration at its manufacturing facilities in Chennai, India, enabling Sanmina to manufacture finished medical instruments and devices in India. Sanmina becomes the first tier 1 EMS (Electronic Manufacturing Services) company to achieve FDA registration in India. Sanmina also operates a product design center in Chennai with an ISO 13485 medical design registration, enabling Sanmina to design medical instruments for its customers, close to its manufacturing facility.

Achieving FDA registration at its Chennai manufacturing facilities is an important milestone that builds on Sanmina's leadership in global medical device and instrument manufacturing. Sanmina manufactures complex products for the world's leading medical OEM companies in over twenty medical manufacturing facilities worldwide and designs medical products in three design centers with ISO 13485 design registrations, including the design center in Chennai. The quality system and audit protocols that come with FDA registration ensure that stringent manufacturing controls and documentation are in place during production of finished medical products to guarantee safety, quality and regulatory control.

"For nearly a decade, Sanmina's Chennai facility has been collaborating with customers to produce innovative medical products," said Charlie Mason, SVP, Medical Market Segment at Sanmina. "Our medical customers can now leverage our extensive capabilities in India to design and deliver finished medical products."

In addition to the medical electronic assemblies and modules that Sanmina already makes, FDA registration authorizes the site to produce finished products such as imaging systems, blood glucose meters, patient monitors and many other complex medical instruments and devices. The FDA registration rounds out a comprehensive list of certifications Sanmina has received in India that include TL 9000, EN/AS 9100, TS 16949 and ISO 13485.

"Sanmina has been at the forefront of product design and manufacturing in India, establishing a proven track record across many industries in one of the fastest growing economies in the world," said Michael Landy, EVP and COO of Integrated Manufacturing Solutions (EMS), Asia and Europe at Sanmina. "The new FDA registration reflects our continued commitment to provide the most comprehensive range of services to OEM customers around the world."

Founded in 2008, the 100-acre campus in Chennai, India is one of the highest technology manufacturing facilities in the region, producing the most advanced medical, communications, industrial, automotive and computing products in the world. Sanmina also operates its India Design Center (IDC) in Chennai. With an ISO 13485 design registration, the IDC is able to design finished medical products and offers a complete range of services, including DFx and test development solutions.

About Sanmina Corporation

Sanmina Corporation is a leading integrated manufacturing solutions provider serving the fastest-growing segments of the global Electronics Manufacturing Services (EMS) market. Recognized as a technology leader, Sanmina provides end-to-end manufacturing solutions, delivering superior quality and support to Original Equipment Manufacturers (OEMs) primarily in the communications networks, storage, industrial, defense, medical, energy and industries that include embedded computing technologies such as, point of sale devices, casino gaming and automotive. Sanmina has facilities strategically located in key regions throughout the world. More information regarding the company is available at http://www.sanmina.com.
 

·
Registered
Joined
·
20,958 Posts
Discussion Starter · #3 ·
Vaccines from Chengalpet complex will meet three-fourths of country's requirements, minister says

CHENNAI: Work on the Integrated Vaccine Complex -- a nodal centre for manufacture and research of vaccines -- in Chengalpet is complete and it will be dedicated to the nation soon, Tamil Nadu health minister C Vijaya Baskar said on Thursday.

The complex will supply vaccines at affordable prices for the centre's Universal Immunisation Programme (UIP). The vaccines manufactured from here would meet three-fourths of the country's requirements, particularly for infants and women, the minister said.

The centre will produce over 500 million doses of pentavalent combination (DPT plus Hep B plus Hib), BCG and other vaccines, the minister said.
 
  • Like
Reactions: MyNation

·
Registered
Joined
·
20,958 Posts
Discussion Starter · #4 ·
Zoho Corp backed vTitan Corporation launches patented syringe infusion pumps

CHENNAI: Zoho Corporation funded healthcare start-up vTitan Corporation today launched its patented syringe infusion pumps designed for patients under critical care.

The company’s Accuflow SP-550 and Accuflow IBP-550 Syringe Infusion Pumps will cater to critical care patients undergoing chemotherapy, heart surgery or taking pain medication among other examples, whose drug dosages need to be administered and monitored precisely.
Read more at:
//economictimes.indiatimes.com/articleshow/62556971.cms?utm_source=contentofinterest&utm_medium=text&utm_campaign=cppst
 

·
Registered
Joined
·
20,958 Posts
Discussion Starter · #6 ·
College of Pharmacy of SRMC&RI gets top tanking from HRD ministry

The College of Pharmacy functioning under the Sri Ramachandra Medical College and Research Institute (SRMC&RI), a deemed university in Chennai, has been ranked 21st on the National Institution Ranking Framework (NIRF) rankings-2018, approved by the ministry of human resources development, government of India.

In the category of medical colleges, SRMC&RI stood 40th and it has been adjudged one among the top ten medical institutes in the country.

The rankings of the Chennai based institutions were declared by the Union HRD minister Prakash Javadekar on April 3 in New Delhi. This was the third edition of the NIRF rankings by the HRD ministry.

While releasing the list of institutions topped high, the minister said government has made participation by public institutions in the NIRF mandatory from next year. The rankings are made in nine categories such as overall performance, universities, engineering institutions, colleges, management institutes, pharmacy colleges, medical institutions, architecture institutes and law institutes.

According to Dr. P.V. Vijayaraghavan, vice chancellor of SRMC&RI, all the recognitions are possible due to the innovative curriculum, skill based training and development of attitudinal skills offered by the deemed university.
 

·
Registered
Joined
·
20,958 Posts
Discussion Starter · #7 ·
Trivitron Health Care's Make in India strategy


Prime Minister Narendra Modi, Tele Inaugurating Trivitron's Labsystems Diagnostics Factory

 

·
Registered
Joined
·
20,958 Posts
Discussion Starter · #8 ·

·
Registered
Joined
·
20,958 Posts
Discussion Starter · #9 · (Edited)
AstraZeneca strengthens innovation partnership in India

AstraZeneca announces an investment of $90 million in India over the next 5 years to develop local skills, build scientific innovation and promote quality manufacturing with the aim to improve overall health outcomes in the country.

At present, AstraZeneca has a workforce of over 4000 employees in India spanning manufacturing, sales and marketing, clinical operations, IT services, digital services and Global medicines development. The company recently announced expansion of its Global Technology Centre (GTC) in Chennai, now employing more than 2000 employees. GTC is AstraZeneca’s first, insourced IT facility.
 

·
Registered
Joined
·
20,958 Posts
Discussion Starter · #11 ·
Impcops to give hands-on training on drug production & identification of raw drugs to Ayush medical students in TN

The Chennai-based Indian Medical Practitioners Co-operative Pharmacy and Stores Ltd (Impcops), which has been manufacturing more than one thousand Ayurveda, Siddha and Unani drugs for decades, will shortly start giving hands-on training on drug making methods and collection, preparation and purification of common plants and mineral substances, to the Ayush medical students of Tamil Nadu.

Prior to the programme, experts from the traditional practitioners’ society will visit each academic institution and give awareness classes to the students and faculties there. They will talk on mainly on how to prepare classical and proprietary drugs in the conventional way, and how to identify genuine raw drugs required for medicine preparation. According to Impcops sources, many manufacturing companies of Ayush drugs use fake raw drugs and it seems very difficult to differentiate the original from the duplicate materials. Students who are the future practitioners and manufacturers need to study this area, sources said.

Speaking to Pharmabiz, Dr R Kannan, president of Impcops, said the medicos in the Ayush institutions have little knowledge about preparation of medicines and identification of medicinal plants. Taking this aspect as big lacunae in the curriculum of Ayush education, Impcops has now decided to give training and awareness classes to the students of BSMS and BAMS. The third and fourth year students of the Siddha, Unani and Ayurveda medical colleges are selected for the training programme.

To begin with, the Society will hold awareness classes for the students and faculties of the Siddha Medical College in Munchirai in Kanyakumari district and Government Ayurveda Medical College in Nagercoil on April 19. Each institution will have two hour classes on production of traditional medicines, collection, identification and preservation of raw drugs, and on how to grow medicinal plants and herbs. A team of experts from Impcops, including its president Dr R Kannan and secretary, Dr K Ponsingh, will speak on different areas.

In the second phase, the third and fourth year students and faculties of the colleges will be invited to the production unit of the Impcops in Chennai to impart the methods of preparation. They will know how to identify pure raw materials and how to preserve it. The various drug making stages will benefit the students to become expert healers.

“Drug making uses a range of methods for preparing the herbs depending on how they will be used. Each method maintains the potencies of the herbs in different ways. Since diverse nature is in the process of preparation, the medical students need to learn the different stages of traditional drug making. We are making an opportunity for the Ayush medicos of all institutions in Tamil Nadu to gain knowledge about it,” said Dr Kannan.

Dr K Ponsingh, secretary of the Society, who is also an expert in different types of drug manufacturing, has explained that the training programme will make the participants understand how to assess the quality of raw drugs and mineral substances, how to determine correct dosage and different types of preparations of Siddha, Unani and Ayurveda drugs. There are specific directions for how to use the medicines like churna (powder), vati (pills), kalka (paste), swaras (fresh juice), kashaya (decoction) and cough syrups. These lessons are also included in the modules of the training programme.

The main reason to start a training programme for the medical students, according to Dr Kananan, is because of the poor industry-institution relation in Ayush sector in Tamil Nadu. He said no manufacturing industry in the state is willing to provide training to students in drug making. Impcops is a very big organization with all modern facilities and gradually it will expand the awareness classes and training to all the Ayush medical colleges.

The training programme will be of 15 days duration where the students will learn the preparation of drugs and post-manufacturing activities like encapsulation. Each participant will have to pay a small amount towards training fee.
 
  • Like
Reactions: vv20298

·
Registered
Joined
·
20,958 Posts
Discussion Starter · #12 ·
‘Asia Labex 2018’ from today

Asia Labex 2018, an exhibition-cum-conference on laboratory, scientific, analytical, research, diagnostic and biotechnology instruments, chemicals and consumables will be held from April 19 to 21 at Chennai Trade Centre. The objective of the event is to bring buyers, scientists, laboratory professionals and decision-makers of key industries and institutions in one platform. More than 150 exhibitors from five countries will showcase their products, solution and services. Along side the exhibition, there is also a two-day conference on ‘New techniques and technology used by laboratory fraternity for testing purposes.
 

·
Registered
Joined
·
20,958 Posts
Discussion Starter · #13 ·
Caplin Point exploring fund raising opportunities

The company is either looking to partner this facility with manufacturer or front-end partner or a possible fundraising by way of stake sale of full divestment.

Pharma company, Caplin Point, informed that its board will meet on March 12, 2018, to explore potential investment opportunities and knowhow of the potential partners for its facility located in Gummidipoondi, Tamil Nadu. Gummidipoondi is Caplin Point’s ambitious project in which the company has invested Rs110cr, completely through accruals. Company expects annual operating expenditure of about Rs60cr for this unit and intends to enter the US market in 2019.

Gummidipoondi facility is capable of manufacturing liquid injectables in vials, Ampoules, Lyophilized Vials and Ophthalmic dosages. This facility received USFDA approval in 2017 and has also been approved by EUGMP and ANVISA-Brazil.

This facility, also called CP-IV, also has an in-house R&D facility dedicated to the development of injectables and ophthalmics for the regulated markets.

Three possibilities emerge according to us. The company is either looking to partner this facility with manufacturer or front-end partner or a possible fundraising by way of stake sale. The third remote possibility is if the company is seeking to divest this unit, which could fetch better valuation considering that this is a brand new unit with the USFDA as well as other regulated market approvals.

At the time when most pharma companies were focussed on the US markets, Caplin adopted a differentiated strategy to focus on less regulated LATAM, African and Caribbean countries, which contributed 90% of its FY17 revenue. The stock has been multi-bagger (~2.9x over past three years) owing to its differentiated strategy. The company now intends to foray in complex and simple injectable ANDAs (volume play with attractive margins).

The company currently enjoys 35%+ EBITDA margins and injectable opportunities should be margin accretive if executed properly with the strict regulatory compliance. The company currently has a healthy balance sheet with total liquid assets over Rs140cr.
 

·
Registered
Joined
·
20,958 Posts
Discussion Starter · #15 ·
Government proposes bailout plan for medical science park


Chennai: The state government has proposed a bailout plan for Frontier Mediville, a medical science park established over 370 acres of land at Elavoor village in Tiruvallur district by cardiac surgeon Dr K M Cherian. The state-owned Tamil Nadu Industrial Development Corporation (TIDCO) and Tamil Nadu Dr MGR University will pump in a minimum of Rs 25 crore each, which will later be converted into equity, towards a one-time settlement (OTS) to banks, which have claimed dues of Rs 156 crore.

Additional chief secretary K Shanmugam has instructed the Tamil Nadu Infrastructure Fund Management Corporation, a nodal agency that coordinates implementation of infrastructure projects in the state, to negotiate with banks and prepare a business model for the science park.

“Banks have invoked powers of legislation to seek liquidation of Frontier Mediville through the National Company Law Tribunal. We worked out a meltdown value of the project and are basing our plans on that. We believe that if the government tells the banks we are interested in the project, the banks may not move ahead with the winding up proceedings,” said a senior finance department official.

It has been estimated that the OTS could come to Rs 50 crore. However, any variation in the final negotiated settlement with the banks will be borne equally by the state medical university and TIDCO, he added.

In September 2016, Dr Cherian requested the state to consider Frontier Mediville as the medicity project envisaged by former chief minister J Jayalalithaa. “Instead of planning something from scratch, it would be good to go with an existing project. But we understand there are a lot of legal tangles and takeover may not be easy,” said Shanmugam.

The General Framework Agreement – a preliminary agreement to show intent to invest by the government and to facilitate undertaking detailed due diligence – was then drafted, as proposed in the government order issued in July 2017. A copy of the agreement and the order is available with ToI.

On March 14, a discussion meeting in the presence of senior officials from the departments of urban development, finance, TIDCO, state medical university and Frontier Lifeline was held to identify financial partners for investment.

“It is important for the government to save this research park because we are not getting adequate help from the banks. We have several ongoing research studies including one on bio-prosthetic valve and artificial heart that can bring down costs of treatment. It would be a Made in India project as well,” said Dr Cherian.
 
  • Like
Reactions: ChnSenthil

·
Registered
Joined
·
20,958 Posts
Discussion Starter · #16 ·
Trivitron to set up new facilities across India

The company will be adding one manufacturing facility in Chennai to make operation room equipment with an investment of Rs15 crore.

Chennai-based medical diagnostics company Trivitron Healthcare is planning to invest Rs100 crore in the next 12-18 months, which will go into creating new manufacturing facilities and rolling out new products.

Through nine manufacturing facilities spread across India, Finland, and Turkey, Trivitron manufactures products across IVD segment, imaging products (ultrasound/X-ray/X-ray accessories), radiation protection products, intensive care (ICU), operation theatre, dialysis, and newborn screening products.

The company will be adding two more manufacturing facilities, one in Chennai to make operation room equipment with an investment of Rs15 crore.

Another facility will come up in Pune which will make X-ray equipment. The company is waiting for approvals for this facility. In the coming 1-2 years, Trivitron plans to develop a series of new products that will include point-of-care devices, self-testing devices for thyroid and other disorders and deficiencies.
 

·
Registered
Joined
·
871 Posts
Orchid Pharma gets EIR from USFDA for its Chennai facility

NEW DELHI: Drug firm Orchid Pharma today said it has received Establishment Inspection Report (EIR) from the US health regulator for its Chennai facility.

The company has received the EIR from the United States Food and Drug Administration (USFDA) on successful inspection closure for the post-marketing adverse drug experience reporting inspection (PADE) conducted at Nungambakkam, Chennai facility, Orchid Pharma said in a BSE filing.

"The facility was inspected by USFDA in the month of June, 2017, it added.

As per the USFDA, after the completion of an inspection of a facility, an EIR is issued to a company detailing inspectional findings.
 
1 - 20 of 113 Posts
Top